Human medicines European public assessment report (EPAR): Retacrit, epoetin zeta, Date of authorisation: 18/12/2007, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Tafamidis Accord, tafamidis, Status: Opinion

Human medicines European public assessment report (EPAR): Ruxolitinib Viatris, ruxolitinib hemifumarate, Status: Opinion

Human medicines European public assessment report (EPAR): Riociguat Accord, riociguat, Status: Opinion

Human medicines European public assessment report (EPAR): Pluvicto, lutetium (177Lu) vipivotide tetraxetan, Date of authorisation: 09/12/2022, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Yondelis, trabectedin, Date of authorisation: 17/09/2007, Revision: 29, Status: Authorised

Questions and answers for biological medicinal products

Human medicines European public assessment report (EPAR): Intrarosa, prasterone, Date of authorisation: 08/01/2018, Revision: 8, Status: Authorised

Paediatric Committee (PDCO): 19-22 May 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 19 May 2026 to 22 May 2026

Committee for Medicinal Products for Human Use (CHMP): 20-23 July 2026, European Medicines Agency, Amsterdam, the Netherlands, from 20 July 2026 to 23 July 2026